+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Controlled Substance Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

  • ID: 4911413
  • Report
  • November 2019
  • Region: Global
  • 206 pages
  • Transparency Market Research
1 of 3

FEATURED COMPANIES

  • AbbVie, Inc.
  • Ampac Fine Chemicals
  • F. Hoffmann-La Roche AG
  • GW Pharmaceuticals plc
  • Mallinckrodt plc
  • Merck & Co., Inc.
  • MORE
Controlled Substance Market - Scope of the Report

The report on the global controlled substance market studies the past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the said market for the forecast period of 2019 to 2027. The report provides the overall market revenue of the global controlled substance market for the period of 2017 - 2027, with 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global controlled substance market for the forecast period.

The controlled substance market report has been prepared after extensive primary and secondary research. Primary research involves bulk of the research efforts, wherein, analysts carry out interviews with key opinion leaders, industry leaders, and opinion makers. Extensive secondary research involves referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global controlled substance market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have employed a combination of the top-down and bottom-up approach to study various phenomena in the global controlled substance market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study of the controlled substance market. Furthermore, the report sheds light on the changing competitive dynamics in the global controlled substance market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the global controlled substance market.

The report delves into the competitive landscape of the global controlled substance market. Key players operating in the global controlled substance market have been identified, and each one of them has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOTs are some of the attributes of players in the global controlled substance market that have been profiled in this report.

Key Questions Answered in the Controlled Substance Market Report
  • What is the sales/revenue generated by each drug across all regions in the controlled substance market during the forecast period?
  • What are the opportunities in the global controlled substance market?
  • What are the major drivers, restraints, opportunities, and threats in the controlled substance market?
  • Which region is likely to expand at the fastest CAGR in the global controlled substance market during the forecast period?
  • Which controlled substance drug and application segments are expected to generate the highest revenue, globally, in 2027? Which segment is projected to expand at the highest CAGR during the forecast period?
  • What was the market share or position of different companies operating in the global controlled substance market in 2018?
Global Controlled Substance Market - Research Objectives and Research Approach

The comprehensive report on the global controlled substance market begins with an overview of the said market, followed by the scope and objectives of this study. Following this, the report provides a detailed explanation of the objectives behind this study, regulatory scenario, pipeline analysis of upcoming different scheduled drugs for medical use, and key mergers & acquisitions to combat in the market.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into small sections. The entire report comprises an exhaustive collection of graphs and tables appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows the comparison of the market shares of key segments in the past and at the end of the forecast period.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie, Inc.
  • Ampac Fine Chemicals
  • F. Hoffmann-La Roche AG
  • GW Pharmaceuticals plc
  • Mallinckrodt plc
  • Merck & Co., Inc.
  • MORE
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Controlled Substance Market

4. Market Overview
4.1. Introduction
4.1.1. Class Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Controlled Substance Market Analysis and Forecasts, 2017–2027
4.4.1. Market Revenue Projections (US$ Mn)

5. Market Outlook
5.1. Pipeline Analysis
5.2. Key Merger & Acquisition
5.3. Regulatory Scenario

6. Global Controlled Substance Market Analysis and Forecasts, by Drug, 2017-2027
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug, 2017–2027
6.3.1. Opioids
6.3.1.1. Codeine
6.3.1.2. Morphine
6.3.1.3. Fentanyl
6.3.1.4. Hydrocodone
6.3.1.5. Tramadol
6.3.1.6. Oxycodone
6.3.1.7. Others
6.3.2. Stimulants
6.3.2.1. Amphetamine
6.3.2.2. Methylphenidate
6.3.2.3. Dextroamphetamine
6.3.2.4. Methamphetamine
6.3.2.5. Modafinil
6.3.2.6. Others
6.3.3. Depressants
6.3.3.1. Barbiturates
6.3.3.2. Benzodiazepines
6.3.4. Cannabinoids
6.4. Market Attractiveness, by Drug

7. Global Controlled Substance Market Analysis and Forecasts, by Application, 2017-2027
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017–2027
7.3.1. ADHD
7.3.2. Pain Management
7.3.3. Depression
7.3.4. Sleep Disorder
7.3.5. Cough Suppression
7.3.6. Anxiety
7.3.7. Seizure
7.3.8. Others
7.4. Market Attractiveness, by Application

8. Global Controlled Substance Market Analysis and Forecasts, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2027
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness, by Application

9. Global Controlled Substance Market Analysis and Forecasts, by Region, 2017-2027
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness, by Region

10. North America Controlled Substance Market Analysis and Forecast, 2017-2027
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug, 2017–2027
10.2.1. Opioids
10.2.1.1. Codeine
10.2.1.2. Morphine
10.2.1.3. Fentanyl
10.2.1.4. Hydrocodone
10.2.1.5. Tramadol
10.2.1.6. Oxycodone
10.2.1.7. Others
10.2.2. Stimulants
10.2.2.1. Amphetamine
10.2.2.2. Methylphenidate
10.2.2.3. Dextroamphetamine
10.2.2.4. Methamphetamine
10.2.2.5. Modafinil
10.2.2.6. Others
10.2.3. Depressants
10.2.3.1. Barbiturates
10.2.3.2. Benzodiazepines
10.2.4. Cannabinoids
10.3. Market Value Forecast, by Application, 2017-2027
10.3.1. ADHD
10.3.2. Pain Management
10.3.3. Depression
10.3.4. Sleep Disorder
10.3.5. Cough Suppression
10.3.6. Anxiety
10.3.7. Seizure
10.3.8. Others
10.4. Market Value Forecast, by Distribution Channel, 2017-2027
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2017-2027
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug
10.6.2. By Application
10.6.3. By Distribution Channel
10.6.4. By Country

11. Europe Controlled Substance Market Analysis and Forecast, 2017-2027
11.1. Introduction
11.1.1. Key Finding
11.2. Market Value Forecast, by Drug, 2017-2027
11.2.1. Opioids
11.2.1.1. Codeine
11.2.1.2. Morphine
11.2.1.3. Fentanyl
11.2.1.4. Hydrocodone
11.2.1.5. Tramadol
11.2.1.6. Oxycodone
11.2.1.7. Others
11.2.2. Stimulants
11.2.2.1. Amphetamine
11.2.2.2. Methylphenidate
11.2.2.3. Dextroamphetamine
11.2.2.4. Methamphetamine
11.2.2.5. Modafinil
11.2.2.6. Others
11.2.3. Depressants
11.2.3.1. Barbiturates
11.2.3.2. Benzodiazepines
11.2.4. Cannabinoids
11.3. Market Value Forecast, by Application, 2017-2027
11.3.1. ADHD
11.3.2. Pain Management
11.3.3. Depression
11.3.4. Sleep Disorder
11.3.5. Cough Suppression
11.3.6. Anxiety
11.3.7. Seizure
11.3.8. Others
11.4. Market Value Forecast, by Distribution Channel, 2017-2027
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017-2027
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug
11.6.2. By Application
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region

12. Asia Pacific Controlled Substance Market Analysis and Forecast, 2017-2027
12.1. Introduction
12.1.1. Key Finding
12.2. Market Value Forecast, by Drug, 2017-2027
12.2.1. Opioids
12.2.1.1. Codeine
12.2.1.2. Morphine
12.2.1.3. Fentanyl
12.2.1.4. Hydrocodone
12.2.1.5. Tramadol
12.2.1.6. Oxycodone
12.2.1.7. Others
12.2.2. Stimulants
12.2.2.1. Amphetamine
12.2.2.2. Methylphenidate
12.2.2.3. Dextroamphetamine
12.2.2.4. Methamphetamine
12.2.2.5. Modafinil
12.2.2.6. Others
12.2.3. Depressants
12.2.3.1. Barbiturates
12.2.3.2. Benzodiazepines
12.2.4. Cannabinoids
12.3. Market Value Forecast, by Application, 2017-2027
12.3.1. ADHD
12.3.2. Pain Management
12.3.3. Depression
12.3.4. Sleep Disorder
12.3.5. Cough Suppression
12.3.6. Anxiety
12.3.7. Seizure
12.3.8. Others
12.4. Market Value Forecast, by Distribution Channel, 2017-2027
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017-2027
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug
12.6.2. By Application
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region

13. Latin America Controlled Substance Market Analysis and Forecast, 2017-2027
13.1. Introduction
13.1.1. Key Finding
13.2. Market Value Forecast, by Drug, 2017-2027
13.2.1. Opioids
13.2.1.1. Codeine
13.2.1.2. Morphine
13.2.1.3. Fentanyl
13.2.1.4. Hydrocodone
13.2.1.5. Tramadol
13.2.1.6. Oxycodone
13.2.1.7. Others
13.2.2. Stimulants
13.2.2.1. Amphetamine
13.2.2.2. Methylphenidate
13.2.2.3. Dextroamphetamine
13.2.2.4. Methamphetamine
13.2.2.5. Modafinil
13.2.2.6. Others
13.2.3. Depressants
13.2.3.1. Barbiturates
13.2.3.2. Benzodiazepines
13.2.4. Cannabinoids
13.3. Market Value Forecast, by Application, 2017-2027
13.3.1. ADHD
13.3.2. Pain Management
13.3.3. Depression
13.3.4. Sleep Disorder
13.3.5. Cough Suppression
13.3.6. Anxiety
13.3.7. Seizure
13.3.8. Others
13.4. Market Value Forecast, by Distribution Channel, 2017-2027
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast by Country/Sub-region, 2017-2027
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug
13.6.2. By Application
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region

14. Middle East & Africa Controlled Substance Market Analysis and Forecast, 2017-2027
14.1. Introduction
14.1.1. Key Finding
14.2. Market Value Forecast, by Drug, 2017-2027
14.2.1. Opioids
14.2.1.1. Codeine
14.2.1.2. Morphine
14.2.1.3. Fentanyl
14.2.1.4. Hydrocodone
14.2.1.5. Tramadol
14.2.1.6. Oxycodone
14.2.1.7. Others
14.2.2. Stimulants
14.2.2.1. Amphetamine
14.2.2.2. Methylphenidate
14.2.2.3. Dextroamphetamine
14.2.2.4. Methamphetamine
14.2.2.5. Modafinil
14.2.2.6. Others
14.2.3. Depressants
14.2.3.1. Barbiturates
14.2.3.2. Benzodiazepines
14.2.4. Cannabinoids
14.3. Market Value Forecast, by Application, 2017-2027
14.3.1. ADHD
14.3.2. Pain Management
14.3.3. Depression
14.3.4. Sleep Disorder
14.3.5. Cough Suppression
14.3.6. Anxiety
14.3.7. Seizure
14.3.8. Others
14.4. Market Value Forecast, by Distribution Channel, 2017-2027
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017-2027
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug
14.6.2. By Application
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region

15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Position/Ranking Analysis by Company (2018)
15.3. Company Profiles
15.3.1. F. Hoffmann-La Roche AG
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Company Financials
15.3.1.3. Growth Strategies
15.3.1.4. SWOT Analysis
15.3.2. AbbVie, Inc.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Company Financials
15.3.2.3. Growth Strategies
15.3.2.4. SWOT Analysis
15.3.3. Mallinckrodt plc
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Company Financials
15.3.3.3. Growth Strategies
15.3.3.4. SWOT Analysis
15.3.4. Pfizer, Inc.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Company Financials
15.3.4.3. Growth Strategies
15.3.4.4. SWOT Analysis
15.3.5. Sun Pharmaceutical Ltd.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Company Financials
15.3.5.3. Growth Strategies
15.3.5.4. SWOT Analysis
15.3.6. Ampac Fine Chemicals
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Company Financials
15.3.6.3. Growth Strategies
15.3.6.4. SWOT Analysis
15.3.7. GW Pharmaceuticals plc
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Company Financials
15.3.7.3. Growth Strategies
15.3.7.4. SWOT Analysis
15.3.8. Merck & Co., Inc.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Company Financials
15.3.8.3. Growth Strategies
16.3.8.4. SWOT Analysis

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • F. Hoffmann-La Roche AG
  • AbbVie, Inc.
  • Mallinckrodt plc
  • Pfizer, Inc
  • Sun Pharmaceutical Ltd.
  • Ampac Fine Chemicals
  • GW Pharmaceuticals plc
  • Merck & Co., Inc.
Note: Product cover images may vary from those shown
Adroll
adroll